KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacira BioSciences (PCRX) Research & Development: 2009-2024

Historic Research & Development for Pacira BioSciences (PCRX) over the last 16 years, with Dec 2024 value amounting to $81.6 million.

  • Pacira BioSciences' Research & Development rose 35.92% to $26.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $103.4 million, marking a year-over-year increase of 34.04%. This contributed to the annual value of $81.6 million for FY2024, which is 6.98% up from last year.
  • As of FY2024, Pacira BioSciences' Research & Development stood at $81.6 million, which was up 6.98% from $76.3 million recorded in FY2023.
  • Over the past 5 years, Pacira BioSciences' Research & Development peaked at $84.8 million during FY2022, and registered a low of $55.5 million during FY2021.
  • Its 3-year average for Research & Development is $80.9 million, with a median of $81.6 million in 2024.
  • Its Research & Development has fluctuated over the past 5 years, first fell by 17.61% in 2020, then surged by 52.66% in 2022.
  • Over the past 5 years, Pacira BioSciences' Research & Development (Yearly) stood at $59.4 million in 2020, then dropped by 6.52% to $55.5 million in 2021, then surged by 52.66% to $84.8 million in 2022, then fell by 10.07% to $76.3 million in 2023, then grew by 6.98% to $81.6 million in 2024.